Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Connect Biopharma Holdings Ltd
Research & Development
Connect Biopharma Holdings Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
|
Research & Development
-¥28.5m
|
CAGR 3-Years
62%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Research & Development
-¥13.6B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Research & Development
-¥2.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Research & Development
-¥1.4B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Research & Development
-¥1.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Research & Development
-¥1.2B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Connect Biopharma Holdings Ltd
Glance View
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 108 full-time employees. The company went IPO on 2021-03-19. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. The company is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The firm mainly conducts its businesses in the China market.
See Also
What is Connect Biopharma Holdings Ltd's Research & Development?
Research & Development
-28.5m
CNY
Based on the financial report for Dec 31, 2024, Connect Biopharma Holdings Ltd's Research & Development amounts to -28.5m CNY.
What is Connect Biopharma Holdings Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
23%
Over the last year, the Research & Development growth was 46%. The average annual Research & Development growth rates for Connect Biopharma Holdings Ltd have been 62% over the past three years , 23% over the past five years .
